chrisvoncsefalvay/vaers-outcomes huggingface dataset:
6/13/2008 clinic visit with complaint of rash on both arms.  Physicians notes: right arm with 12cm. x 8cm. erythema with warmth on right humerus.  Two puncture marks were vaccines were given were in upper part of erythema.  Diagnosis: cellulitis.  MD ordered: trimethoprim - sulfamethoxazole 160-800mg 1 tab 2x 1 day x10 days.
Fever spike 101 F; Fever spike 101 F; Fever spike 100 F; Headache; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever spike 100 F), the second episode of PYREXIA (Fever spike 101 F), HEADACHE (Headache) and the first episode of PYREXIA (Fever spike 101 F) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Apr-2021, the patient experienced PYREXIA (Fever spike 100 F) and HEADACHE (Headache). On 07-Apr-2021, the patient experienced the first episode of PYREXIA (Fever spike 101 F). On 09-Apr-2021, the patient experienced the second episode of PYREXIA (Fever spike 101 F). On 04-Apr-2021, PYREXIA (Fever spike 100 F) had resolved. On 09-Apr-2021, last episode of PYREXIA (Fever spike 101 F) and HEADACHE (Headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Pyrexia: 100 Farad (High) fever on Sun (100F), 101 Farad (High) Wed spike of 101 and 101 Farad (High) Friday spike of 101.         Concomitant product use was not provided by the reporter. Treatment information included tylenol for headache.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Fatigued; Headache; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Fatigued) and HEADACHE (Headache) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039D21A and 039D21A) for COVID-19 vaccination.     No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, the patient experienced FATIGUE (Fatigued) and HEADACHE (Headache). On 27-Oct-2021, FATIGUE (Fatigued) and HEADACHE (Headache) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment medication use was reported.
Vaccination Adverse Reaction; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Vaccination Adverse Reaction) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (Vaccination Adverse Reaction). At the time of the report, IMMUNISATION REACTION (Vaccination Adverse Reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.   No treatment information was provided.  This case was identified as part of a retrospective clean-up activity received in the Moderna were missed to be booked-in.
Was taking Macrobid at time of Moderna injection in Feb. 4 months later, I needed to take Macrobid again and started getting dermatographia and general hives 4 days after I finished the course. No idea if Moderna or Macrobid are related but no other medication or life style change has occurred. Dermatographia/hives are very itchy and require 3 doses of Zyrtec to not itch. They started on June 17th and have yet to go away, so about 2.5 months of hives.
2.5 days p/vax pt devel right cheek pain & swelling. given med & days off work
Pregnant; This spontaneous prospective pregnancy case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011J20A and 028L20A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (allergic to erythromycin...).   On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 03-Jun-2021. On 04-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). On 04-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Pregnancy test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient would like to enroll into the pregnancy registry for the mRNA-1273 vaccine.  The patient's date of positive pregnancy, last menstrual period date and conception date were all not provided. No treatment information was reported. Internal review conducted on 23jul2021 resulted in updates to pregnancy information  This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Rigid right thigh muscle to the point of almost unable to walk, very very poor urinary sphincter control . Lasted around 30 hours.
This spontaneous report as received from a consumer refers to a  17 year old female patient via social media. Patient's medical history, concurrent conditions and drug reactions/allergies were not reported. On an unknown date, the patient was vaccinated with a dose of GARDASIL (lot #, expiration date, dose and route of administration were not reported). Patient's concomitant medication was not reported. On an unknown date, the patient experienced an unspecified adverse event (reported as another life ruined by the GARDASIL vaccine). The outcome of the unspecified event was not reported. The reporter did not provided the relationship between the unspecified event and GARDASIL. A product quality complaint was not involved. This is one of two reports received from the same reporter. Additional information is not expected, as there is no contact information.
Employee had no adverse reaction. Staff told me that we need to complete this form about event. 1/4/21 Patient got injection with Agency, consent she completed stated she had never received a covid vaccine of any type. When I went to enter into database it showed she got one 12/30 at the Hospital. I called her Immediately and she told me she had filled out the consent at Hospital but injections were not ready when she got off night shift so she left and did not get it. By Wednesday her story changed to she got it there and at Agency.
Significant increase in Arthritis in my hands, lower back, neck and toes.  2% Voltarol gives temporary relief.
Patient said after getting the vaccine she is now experiencing ringing in her ears. Not sure when it started exactly but it was after receiving the vaccine.
pt recv vax;devel facial paralysis & pain,dx of Bell's palsy;recv 3rd dose;approx 11nov93,devel facial paralysis & discomfort;neurologist said recurrent Bell's palsy;tx w/ pred;recovered fully; lab eval showed anti HBs 38.8 RU;
Redness, swellling, pruritis 7 days after 1st dose of Covid-19 moderna vaccine in ipsilateral arm at injeciton site.
Pt with 2 month history of intermittent shaking chills on multiple meds status post liver transplant 6 years ago. Ten minutes after shot developed lightheadedness, shaking chills similar to prior episodes associated with moderate hypotension and bradycardia, supine position, observation, self-medication with valium, resolved in one hour.
Tired; Not Well; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 10Mar2021 at 14:00 as a single dose for COVID-19 immunisation. Medical history included blood pressure. The patient had no known allergies. The patient received unspecified medications within two weeks of vaccination. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. On 08Dec2020, the patient underwent nasal swab test and the result was positive. On 10Mar2021 at 16:00 the patient experienced tired, not well and nausea. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of events tired, not well and nausea was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Arm went red immediately and a hive about the size of a quarter appeared. No other problems after MMR on right arm. Went away after about 1 hr.
No adverse event; Monovalent doses administered after the BUD to patients; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patients) and NO ADVERSE EVENT (No adverse event) in a 41-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 058A22-2A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Jul-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 07-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patients). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patients) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patients).    No relevant concomitant medications were reported.  No treatment information was provided.
18 yo healthy male who received SPV #1 (lot# VV03019C) on 26 JUN 2019 in addition to Typhoid #1. Our office was contacted by provider due to concern for autoinoculation with lesions at his axilla, nares (L), bridge of nose, Left ear and left thigh. He developed an initial lesion at initial R deltoid vaccine site (normal): 01 JUL 2019. He states this was above the inoculation site and he thought it was a normal acne pustule so he "popped" it.  He noted a  2nd site (R Axilla) on 04 JUL, 3rd Site  at the bridge of his nose, which he also popped on 04 JUL 2019. This site became large and ulcerated by 06 JUL 19. A 4th site  to his L nare  appeared also 06 JUL 19. A 5th site of an erythematous tender papule appeared 07 JUL 17  and a 6th site to his L medial thigh appeared 07 JUL.
Tired; weakness; his is a spontaneous report from a contactable consumer. A 43-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot number: ER8727 and expiration dates were not reported), dose 1 via an unspecified route of administration in arm left on 13Apr2021 at 14:00 as single dose for COVID-19 immunisation. The patient's medical history included thyroid, hashimoto and allergy to penicillin and Levaquin from an unknown date and unknown if ongoing. The concomitant medication included levothyroxine sodium (SYNTHROID), clonazepam (KLONOPIN), escitalopram oxalate (LEXAPRO) and buspirone hydrochloride (BUSPAR) all products from an unknown date for an unknown indication. On 13Apr2021 at 14:00 the patient experienced tired and weakness for about a week after 1 dose of vaccine. The facility where the most recent COVID-19 vaccine was administered id reported as other. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received corrective treatment for the adverse event. The patient underwent lab test and procedure that is Heart rate: increase and blood pressure measurement: 145/95 +/- 10. The outcome of the events were not recovered.   No Follow-up attempts are needed. No further information is expected.
WHEEZING; DIZZINESS; SPINNING; HEADACHE; NAUSEA; This spontaneous report received from a patient concerned a 27 year old male. The patient's weight was 180 pounds, and height was 73 inches. The patient's pre-existing medical conditions included the patient had no history of medical issues.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802086, and batch number: 1802086 expiry: UNKNOWN) dose was not reported, administered to the left arm, on 25-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, Laboratory data included: COVID-19 virus test (NR: not provided) Negative. On 25-MAR-2021, the subject experienced wheezing. On 25-MAR-2021, the subject experienced dizziness. On 25-MAR-2021, the subject experienced spinning. On 25-MAR-2021, the subject experienced headache. On 25-MAR-2021, the subject experienced nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headache, wheezing, dizziness, spinning, and nausea. This report was non-serious.
71yo female resident who died after receiving Pfizer BioNTech vaccine.  On 1/14/2021, VS taken at 10am, B/P 99/60, O2 sats, 95% (trach w/O2). At 11:30am, Patient showed no s/sx of distress, A&Ox3.  At 11:50am, a nurse went to perform a COVID test and assessment (the facility is experiencing an outbreak), and found the patient unresponsive on the bathroom floor.  CPR was immediately started; no shock advised per AED; 12:15pm EMS arrived and took over.  At 12:38pm, EMT called time of death.
Case number PHHY2011US49518, is an initial spontaneous report from a nurse received on 25 May 2011. The patient was vaccinated with MENVEO (batch number 090701) on 23 May 2011. The patient received only the Men CYW-135 liquid vaccine component. No other information was reported.
Vein swelling in both legs, between ankle and calf on the outside.  Never had anything like this before
doses administered after more than 1 temperature excursion; doses administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-May-2021 at 9:08 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 24-May-2021 at 9:08 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient age was reported as 64.01 years. No concomitant medication was reported. It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.  On 3-May-2021, total doses given for the day were 39 degree F. Condition of vaccine prior to administration was reported not frozen. Vaccine moved to fridge on   vail was moved to clinic on 03-May-2021. Vails were moved to clinic 24-May-2021. Vaccine BUD date was reported as 02-Jun-2021.  On 24-May-2021, vaccine excursion time was at 8 AM and 9 AM at 35 degree F.  No treatment information was reported.
At about 10 AM the day after I received the vaccine, I experienced extreme stomach pains, nausea, low grade fever and chills. The following day, the stomach pains lessened but were still present and I was nauseous. Symptoms went away on Sunday 1/17.
Very bad pain in neck and at base of skull.  Could barely move my head from side to side, incredible pain in cervical area of my neck when lifting my head off the pillow or turning over in bed.  Also some pain in middle and lower part of my spine.
Swelling / goes into the axilla and has a "formation"; Redness / erythema around the entire left upper arm where he got the injection; Pain; This case was reported by a physician via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA197A, expiry date 31st October 2020) for prophylaxis.   On 26th February 2020, the patient received the 1st dose of Menveo (intramuscular). In February 2020, less than a week after receiving Menveo, the patient experienced extensive swelling of vaccinated limb, erythema of extremities and pain. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the extensive swelling of vaccinated limb was not recovered/not resolved and the outcome of the erythema of extremities and pain were recovering/resolving.   It was unknown if the reporter considered the extensive swelling of vaccinated limb, erythema of extremities and pain to be related to Menveo.  Additional details were reported as follows: The patient was administered his 1st dose of the Menveo vaccine 2 days prior to the reporting. The patient stated that the patient developed swelling and redness below where the vaccine was administered. The reporter stated that the patient was given Benadryl but on day of reporting, the swelling was much bigger and there was erythema around the entire left upper arm where he got the injection. The reporter stated that the area does not felt hard or like cellulitis and that the swelling got into the axilla and had a formation. The patient stated that the patient reported pain. The reporter consented to follow up.
Patient contacted pharmacy after vaccination to report spotting. She stated her period occurred 2 weeks ago. She states she has had spotting ever since she received her second vaccine. She contacted her provider and they advised her to watch and wait. However, she wanted to report this as an adverse event to the pharmacy.
Headache, Fatigue, redness at the injection site Narrative; The employees tested for COVID due to extreme fatigue; the test was negative. The symptoms remain for a week and after one week start to improve---continues to experience headache during the second week.
I started to get severe pain in my hands and feet a couple of weeks after the vaccine.  in the palm of my hand at the base of my fingers, I have been getting sharp stabbing pain. some days it can be so bad  I cannot move my and or use it. It comes and goes. It's not all the time. In my feet, at the balls of my feet, I get the same sharp stabbing pain. it feels like a knife is in my foot. some days it moves to my arches and makes it difficult to walk. sometimes my foot feels frozen from the pain. eventually, it goes away. but it always comes back 4 or 5 times a day.
After 1st and 2nd vaccinations I had a headache and back/muscle aches. After the 2nd dose I also had a more severe headache, tiredness, and brain fog. I was unable to work the next day following that 2nd dose. After the 3rd dose, I had a severe headache, body aches, chills, tiredness, and brain fog. I was unable to work the next day and half following that 3rd dose. About 2 months after the 1st vaccination my skin started to show blistery lesions that changed in appearance as they aged. I was later diagnosed with linear lichen planus. It flared after each subsequent vaccination and each time I contracted COVID. I contracted COVID 2x after my 2nd shot. it has continued to slowly spread across my entire body to include my mouth, privates, and armpits.  I have been treated with oral steroids and am being treated with topical steriods and creams.
Itching, redness, and swelling at the injection sites. 30 mL of liquid diphenhydramine given (error, Poison Control consulted, situation cleared as not requiring medical attention). Client's mother advised to continue monitoring and report incident to pediatrician. Also encouraged to call  EMS is symptoms return/worsen. Client and family discharged to home (ambulatory, A&O) with no itching and significantly reduced redness and swelling.
Saturday and Sunday, I had severe headache (didn't get out of bed). I had a fever of over 103. It got up to 103.8. Those both lasted about a day and a half together.  Monday, I was back at work. I still had a low fever but it was fine by lunchtime. Just took Tylenol for symptoms - it helped some with the fever but it did not help with the headache which was there for a full 2 days. I had a doctor visit last week (on Sept 2) -  I had severe pain in my lower left abdomen (noticed on Sept 1) - and I have an ovarian cyst. It was determined a  year ago but it is much bigger now than it was before and so I have been in a lot of pain. Just OTC medication - like Aleve. The  pain was pretty consistent for about 48 hours but now it's fine.  The doctor will just watch it.
Within seconds of receiving her fourth vaccine (HPV), patient reports feeling like she might pass out.  She has done this before following pain stimulus.  We leaned her back with head of exam table up and feet up.  She closed her eyes and became rigid for about 5 seconds.  Then she became alert and reported she didn't remember what had just happened.  I observed her for another 15 minutes with no further symptoms/signs.
Patient fainted in office, was sitting on bed felt pain on (R) arm and fell forward. Aunt was able to get her before hitting head. She had not eaten nothing that day. We laid pt on bed checked blood pressure vitals everything was normal, stayed in office 30 min.